Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 869 record(s)

Req # A-2022-001197

Adverse Drug Reactions (ADRs). Report numbers: E2B_04281990, 000701188, E2B_02206169.

Organization: Health Canada

26 page(s)
March 2023

Req # A-2022-001244

Adverse Drug Reactions (ADRs). Report numbers: E2B_05801775, E2B_05801788, E2B_05801805, E2B_05801842, E2B_05801941, E2B_05801945, E2B_05801952, E2B_05801957, E2B_05801959, E2B_05801997.

Organization: Health Canada

165 page(s)
March 2023

Req # A-2022-001248

Adverse Drug Reactions (ADRs). Report numbers: E2B_05764304, E2B_05776491, E2B_05791929, 001010673, E2B_05787117, E2B_05771639, E2B_05720884, E2B_05797057, E2B_05752231, E2B_05799455.

Organization: Health Canada

186 page(s)
March 2023

Req # A-2022-001258

Adverse Drug Reactions (ADRs) for FEXOFENADINE HYDROCHLORIDE, BISACODYL, HYOSCINE BUTYLBROMIDE. Report numbers: 00100881, E2B_05856427, 001009337, E2B_05859787.

Organization: Health Canada

246 page(s)
March 2023

Req # A-2022-001261

Adverse Drug Reactions (ADRs). Report numbers: 000994956, E2B_02485004, E2B_05426549, 000996269, 000997021, E2B_05481236, 000998935, E2B_05487837, 000998381, E2B_05508975.

Organization: Health Canada

178 page(s)
March 2023

Req # A-2022-001265

Adverse Drug Reactions (ADRs). Report numbers: 001003681, 001000617, E2B_05605804, E2B_05588911, E2B_05592275, E2B_05556806, E2B_05605856, E2B_05539957, E2B_05539402, E2B_05605792.

Organization: Health Canada

108 page(s)
March 2023

Req # A-2022-001269

Adverse Drug Reactions (ADRs). Report numbers: 001002529, E2B_05560744, E2B_05545952, E2B_05560909, 001003894, 001004239, E2B_03813240, E2B_05605866, E2B_04903649, E2B_05579872.

Organization: Health Canada

194 page(s)
March 2023

Req # A-2022-001270

Adverse Drug Reactions (ADRs). Report numbers: E2B_05609290, E2B_05539854, E2B_05524700, E2B_05524689, E2B_05391424, 001000619, E2B_05539391, E2B_05526994, 001003426, E2B_05418969.

Organization: Health Canada

125 page(s)
March 2023

Req # A-2022-001283

Adverse Drug Reaction (ADR). Report number: E2B_05801876.

Organization: Health Canada

18 page(s)
March 2023

Req # A-2022-001293

Adverse Drug Reactions (ADRs). Report numbers: E2B_03186205, E2B_05863464, E2B_02939494, 001012402, E2B_05766145.

Organization: Health Canada

139 page(s)
March 2023
Date modified: